{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:28:59Z","timestamp":1790908139920,"version":"4.1.0"},"reference-count":67,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral NK\/T-cell neoplasms are an uncommon group of diseases that show distinct racial and geographic variation. The prognostic significance of the T-cell phenotype has been clearly defined in recent studies by using modern lymphoma classification systems. However, within this heterogenous group of neoplasms, some have a more favorable prognosis, such as ALK-positive anaplastic large-cell leukemia (ALCL) and primary cutaneous ALCL, and some have ultimately fatal courses with standard chemotherapy programs (e.g., hepatosplenic \u03b3\u03b4 T-cell lymphomas). Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen. Given disease rarity and biological heterogeneity, advances in diagnosis, prognosis and treatment have lagged behind DLBCL. Recently, however, studies are emerging that focus specifically on PTCLs with the ultimate goal of better understanding disease biology and developing more effective therapies.<\/jats:p>","DOI":"10.1182\/asheducation-2008.1.280","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T15:12:58Z","timestamp":1229008378000},"page":"280-288","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Prognosis and Primary Therapy in Peripheral T-Cell Lymphomas"],"prefix":"10.1182","volume":"2008","author":[{"given":"Kerry J.","family":"Savage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111709500060600_R1","unstructured":"Rappaport H. Tumors of the hematopoietic system. In: Atlas of Tumor Pathology. 3rd section fasc 8. Washington: Armed Forces Institute of Pathology; 1966."},{"key":"2019111709500060600_R2","doi-asserted-by":"crossref","unstructured":"Anonymous. National Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin\u2019s Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112\u20132135.","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"2019111709500060600_R3","doi-asserted-by":"crossref","unstructured":"Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas [letter] [published erratum appears in Lancet 1988 Feb 13;1(8581):372]. Lancet. 1988;1:292\u2013293.","DOI":"10.1016\/S0140-6736(88)90367-4"},{"key":"2019111709500060600_R4","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood. 1994;84:1361\u20131392.","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"2019111709500060600_R5","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997 [see comments]. J Clin Oncol. 1999;17:3835\u20133849.","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"2019111709500060600_R6","doi-asserted-by":"crossref","unstructured":"Kwak LW, Wilson M, Weiss LM, et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. J Clin Oncol. 1991;9:1426\u20131431.","DOI":"10.1200\/JCO.1991.9.8.1426"},{"key":"2019111709500060600_R7","doi-asserted-by":"crossref","unstructured":"Cheng AL, Chen YC, Wang CH, et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades\u2014should peripheral T-cell lymphoma be considered separately? J Clin Oncol. 1989;7:725\u2013731.","DOI":"10.1200\/JCO.1989.7.6.725"},{"key":"2019111709500060600_R8","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA). Blood. 1998;92:76\u201382."},{"key":"2019111709500060600_R9","doi-asserted-by":"crossref","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15:1467\u20131475.","DOI":"10.1093\/annonc\/mdh392"},{"key":"2019111709500060600_R10","doi-asserted-by":"crossref","unstructured":"Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin\u2019s lymphoma. Blood. 1997;89:4514\u20134520.","DOI":"10.1182\/blood.V89.12.4514"},{"key":"2019111709500060600_R11","unstructured":"Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol. 1998;9:849\u2013855."},{"key":"2019111709500060600_R12","doi-asserted-by":"crossref","unstructured":"Morabito F, Gallamini A, Stelitano C, et al. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. Cancer. 2004;101:1601\u20131608.","DOI":"10.1002\/cncr.20531"},{"key":"2019111709500060600_R13","doi-asserted-by":"crossref","unstructured":"Arrowsmith ER, Macon WR, Kinney MC, et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma. 2003;44:241\u2013249.","DOI":"10.1080\/1042819021000030054"},{"key":"2019111709500060600_R14","doi-asserted-by":"crossref","unstructured":"Kim K, Kim WS, Jung CW, et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer. 2002;38:75\u201381.","DOI":"10.1016\/S0959-8049(01)00344-6"},{"key":"2019111709500060600_R15","doi-asserted-by":"crossref","unstructured":"International Peripheral T-Cell and Natural Killer\/T-Cell Lymphoma Study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u20134130.","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"2019111709500060600_R16","doi-asserted-by":"crossref","unstructured":"Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s Lymphoma Classification Project. J Clin Oncol. 1998;16:2780\u20132795.","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"2019111709500060600_R17","doi-asserted-by":"crossref","unstructured":"Kutok JL, Aster JC. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol. 2002;20:3691\u20133702.","DOI":"10.1200\/JCO.2002.12.033"},{"key":"2019111709500060600_R18","unstructured":"Jaffe ES, Railfkiaer E. Mature T-cell and NK neoplasms: introduction In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon; 2001:191\u2013194."},{"key":"2019111709500060600_R19","doi-asserted-by":"crossref","unstructured":"Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913\u20133921.","DOI":"10.1182\/blood.V93.11.3913"},{"key":"2019111709500060600_R20","doi-asserted-by":"crossref","unstructured":"ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination [see comments]. J Clin Pathol. 2000;53:445\u2013450.","DOI":"10.1136\/jcp.53.6.445"},{"key":"2019111709500060600_R21","doi-asserted-by":"crossref","unstructured":"Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T\/null lymphomas (\u201cALK lymphomas\u201d) with a wide morphological spectrum. Am J Pathol. 1998;153:875\u2013886.","DOI":"10.1016\/S0002-9440(10)65629-5"},{"key":"2019111709500060600_R22","unstructured":"Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T\/null cell phenotype [In Process Citation]. Blood. 2000;96:2993\u20133000."},{"key":"2019111709500060600_R23","doi-asserted-by":"crossref","unstructured":"Salaverria I, Bea S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol. 2008;140:516\u2013526.","DOI":"10.1111\/j.1365-2141.2007.06924.x"},{"key":"2019111709500060600_R24","doi-asserted-by":"crossref","unstructured":"Savage KJ, Harris NL, Vose JM, et al. ALK-negative anaplastic large-cell lymphoma (ALCL) is clinically and immunophenotypically different from both ALK-positive ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496\u20135504.","DOI":"10.1182\/blood-2008-01-134270"},{"key":"2019111709500060600_R25","unstructured":"Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinicopathological findings and outcome. Blood. 1999;93:2697\u20132706."},{"key":"2019111709500060600_R26","doi-asserted-by":"crossref","unstructured":"Lamant L, de Reynies A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2007;109:2156\u20132164.","DOI":"10.1182\/blood-2006-06-028969"},{"key":"2019111709500060600_R27","doi-asserted-by":"crossref","unstructured":"Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol. 2004;164:1837\u20131848.","DOI":"10.1016\/S0002-9440(10)63742-X"},{"key":"2019111709500060600_R28","doi-asserted-by":"crossref","unstructured":"ten Berge RL, de Bruin PC, Oudejans JJ, Ossenkoppele GJ, van der Valk P, Meijer CJ. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology. 2003;43:462\u2013469.","DOI":"10.1046\/j.1365-2559.2003.01726.x"},{"key":"2019111709500060600_R29","doi-asserted-by":"crossref","unstructured":"Medeiros LJ, Elenitoba-Johnson KS. Anaplastic large cell lymphoma. Am J Clin Pathol. 2007;127:707\u2013722.","DOI":"10.1309\/R2Q9CCUVTLRYCF3H"},{"key":"2019111709500060600_R30","doi-asserted-by":"crossref","unstructured":"Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM\/ALK: a distinct clinicopathologic entity. Blood. 1995;86:1954\u20131960.","DOI":"10.1182\/blood.V86.5.1954.bloodjournal8651954"},{"key":"2019111709500060600_R31","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Volume 2. IARC WHO Classification of Tumours, No 2. Lyon, France: IARC Press; 2008."},{"key":"2019111709500060600_R32","doi-asserted-by":"crossref","unstructured":"Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768\u20133785.","DOI":"10.1182\/blood-2004-09-3502"},{"key":"2019111709500060600_R33","doi-asserted-by":"crossref","unstructured":"Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49:1049\u20131058.","DOI":"10.1016\/S0190-9622(03)02484-8"},{"key":"2019111709500060600_R34","doi-asserted-by":"crossref","unstructured":"Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10:5494\u20135500.","DOI":"10.1158\/1078-0432.CCR-04-0371"},{"key":"2019111709500060600_R35","doi-asserted-by":"crossref","unstructured":"Tsuchiya T, Ohshima K, Karube K, et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood. 2004;103:236\u2013241.","DOI":"10.1182\/blood-2002-05-1352"},{"key":"2019111709500060600_R36","doi-asserted-by":"crossref","unstructured":"Dupuis J, Emile JF, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) study. Blood. 2006;108:4163\u20134169.","DOI":"10.1182\/blood-2006-04-017632"},{"key":"2019111709500060600_R37","unstructured":"Weisenburger DD, Vose JM, Armitage JO, et al. Peripheral T-cell lymphoma, not otherwise specified: a clinicopathologic study of 340 cases from the International peripheral T-cell lymphoma project [abstract]. Ann Oncol. 2008;19 Supplement 4:113a."},{"key":"2019111709500060600_R38","doi-asserted-by":"crossref","unstructured":"Asano N, Suzuki R, Kagami Y, et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol. 2005;29:1284\u20131293.","DOI":"10.1097\/01.pas.0000173238.17331.6b"},{"key":"2019111709500060600_R39","doi-asserted-by":"crossref","unstructured":"Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472\u20132479.","DOI":"10.1200\/JCO.2005.03.6327"},{"key":"2019111709500060600_R40","doi-asserted-by":"crossref","unstructured":"de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications\u2014a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;1;25:805\u2013812.","DOI":"10.1200\/JCO.2006.09.4490"},{"key":"2019111709500060600_R41","doi-asserted-by":"crossref","unstructured":"Pescarmona E, Pignoloni P, Puopolo M, et al. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. J Pathol. 2001;195:361\u2013366.","DOI":"10.1002\/path.945"},{"key":"2019111709500060600_R42","doi-asserted-by":"crossref","unstructured":"Cuadros M, Dave SS, Jaffe ES, et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol. 2007;2007;25:3321\u20133329.","DOI":"10.1200\/JCO.2006.09.4474"},{"key":"2019111709500060600_R43","doi-asserted-by":"crossref","unstructured":"Martinez-Delgado B, Cuadros M, Honrado E, et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia. 2005;19:2254\u20132263.","DOI":"10.1038\/sj.leu.2403960"},{"key":"2019111709500060600_R44","unstructured":"Banks PM, Warnke RA. Mature T-cell and NK-cell neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoetic and Lymphoid Tissues. IARC Press: Lyon; 2001:189\u2013230."},{"key":"2019111709500060600_R45","doi-asserted-by":"crossref","unstructured":"Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK\/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer. 2005;41:1402\u20131408.","DOI":"10.1016\/j.ejca.2005.03.010"},{"key":"2019111709500060600_R46","doi-asserted-by":"crossref","unstructured":"Yeh KH, Lien HC, Hsu SM, Cheng AL. Quiescent nasal T\/NK cell lymphoma manifested as primary central nervous system lymphoma. Am J Hematol. 1999;60:161\u2013163.","DOI":"10.1002\/(SICI)1096-8652(199902)60:2<161::AID-AJH15>3.0.CO;2-A"},{"key":"2019111709500060600_R47","doi-asserted-by":"crossref","unstructured":"Kim SJ, Kim BS, Choi CW, et al. Ki-67 expression is predictive of prognosis in patients with stage I\/II extranodal NK\/T-cell lymphoma, nasal type. Ann Oncol. 2007;18:1382\u20131387.","DOI":"10.1093\/annonc\/mdm183"},{"key":"2019111709500060600_R48","doi-asserted-by":"crossref","unstructured":"Pagano L, Gallamini A, Trape G, et al. NK\/T-cell lymphomas \u2018nasal type\u2019: an Italian multicentric retrospective survey. Ann Oncol. 2006;17:794\u2013800.","DOI":"10.1093\/annonc\/mdl015"},{"key":"2019111709500060600_R49","doi-asserted-by":"crossref","unstructured":"Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials. Blood. 2008;111:4463\u20134470.","DOI":"10.1182\/blood-2007-08-105759"},{"key":"2019111709500060600_R50","doi-asserted-by":"crossref","unstructured":"Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008;2008;111:838\u2013845.","DOI":"10.1182\/blood-2007-04-087288"},{"key":"2019111709500060600_R51","doi-asserted-by":"crossref","unstructured":"Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102:4261\u20134269.","DOI":"10.1182\/blood-2003-05-1675"},{"key":"2019111709500060600_R52","doi-asserted-by":"crossref","unstructured":"Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474\u20132479.","DOI":"10.1182\/blood-2003-09-3080"},{"key":"2019111709500060600_R53","doi-asserted-by":"crossref","unstructured":"Vose J, The International PTCL Project Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood. 2005;106. Abstract #811.","DOI":"10.1182\/blood.V106.11.811.811"},{"key":"2019111709500060600_R54","doi-asserted-by":"crossref","unstructured":"Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103:216\u2013221.","DOI":"10.1182\/blood-2003-05-1401"},{"key":"2019111709500060600_R55","doi-asserted-by":"crossref","unstructured":"Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612\u2013618.","DOI":"10.1200\/JCO.2005.04.1384"},{"key":"2019111709500060600_R56","doi-asserted-by":"crossref","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;328:1002\u20131006.","DOI":"10.1056\/NEJM199304083281404"},{"key":"2019111709500060600_R57","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626\u2013633.","DOI":"10.1182\/blood-2003-06-2094"},{"key":"2019111709500060600_R58","unstructured":"Schmitz N, Ziepert M, Nickelsen M, et al. T-cell lymphomas in studies of the German High-grade NHL study group (DSHNHL) [abstract]. Ann Oncol. 2008;9 Supp 4:94a."},{"key":"2019111709500060600_R59","doi-asserted-by":"crossref","unstructured":"Gressin R, Peoch M, Deconinck E, et al. The VIP-ABVD Regimen is not superior to the CHOP 21 for the treatment of non epidermotropic peripheral T-cell lymphoma. Final results of the \u201aLTP95\u201d protocol of the GOELAMS [abstract]. Blood. 2006;108. Abstract #2464.","DOI":"10.1182\/blood.V108.11.2464.2464"},{"key":"2019111709500060600_R60","doi-asserted-by":"crossref","unstructured":"Sung HJ, Kim SJ, Seo HY, et al. Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. Br J Haematol. 2006;134:45\u201353.","DOI":"10.1111\/j.1365-2141.2006.06124.x"},{"key":"2019111709500060600_R61","doi-asserted-by":"crossref","unstructured":"Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med. 1998;339:21\u201326.","DOI":"10.1056\/NEJM199807023390104"},{"key":"2019111709500060600_R62","doi-asserted-by":"crossref","unstructured":"You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)\/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004;15:618\u2013625.","DOI":"10.1093\/annonc\/mdh143"},{"key":"2019111709500060600_R63","doi-asserted-by":"crossref","unstructured":"Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma. J Clin Oncol. 2006;24:181\u2013189.","DOI":"10.1200\/JCO.2005.03.2573"},{"key":"2019111709500060600_R64","doi-asserted-by":"crossref","unstructured":"Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer\/T-cell or T-cell lymphoma. Cancer. 2004;100:366\u2013375.","DOI":"10.1002\/cncr.11908"},{"key":"2019111709500060600_R65","doi-asserted-by":"crossref","unstructured":"Au W, Intragumtornchai T, Nakamura S, Armitage JO, Liang R. Clinical and pathological differences between nasal and nasal-type NK\/T cell lymphomas: a summary of 136 cases from the International T Cell Lymphoma (ITCL) Project [abstract]. Blood. 2006;108. Abstract #292.","DOI":"10.1182\/blood.V108.11.292.292"},{"key":"2019111709500060600_R66","doi-asserted-by":"crossref","unstructured":"Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radio-therapy improved survival of localized extranodal NK\/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008;70:166\u2013174.","DOI":"10.1016\/j.ijrobp.2007.05.073"},{"key":"2019111709500060600_R67","doi-asserted-by":"crossref","unstructured":"Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin\u2019s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848\u2013858.","DOI":"10.1182\/blood.V66.4.848.848"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/280\/786522\/280_288ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/280\/786522\/280_288ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T17:28:40Z","timestamp":1589390920000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2008\/1\/280\/95836\/Prognosis-and-Primary-Therapy-in-Peripheral-TCell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2008.1.280","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}